Vaxart Announces Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
Vaxart, Inc. (VXRT)
Last vaxart, inc. earnings: 3/19 04:01 pm
Check Earnings Report
Company Research
Source: Business Wire
Initiation of Two Norovirus Vaccine Trials Expected in 1H 2019 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Vaxart, Inc., a clinical-stage biotechnology company developing oral recombinant vaccines that are administered by tablet rather than by injection, today announced financial results for the fourth quarter and full year ended December 31, 2018. “As we execute on our objective of building a leading oral vaccine company, we continue to expand our understanding of the unique properties of our oral vaccine platform and the important advantages we believe it can offer over conventional injectable vaccines, particularly for mucosal pathogens such as norovirus, flu and RSV,” said Wouter Latour, M.D., chief executive officer of Vaxart. “We are focused on our lead product candidate, the first oral vaccine against norovirus, a disease with a $34 billion economic impact in high income countries inclu
Show less
Read more
Impact Snapshot
Event Time:
VXRT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VXRT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VXRT alerts
High impacting Vaxart, Inc. news events
Weekly update
A roundup of the hottest topics
VXRT
News
- Vaxart to Present at World Vaccine Congress Washington 2024 on April 3GlobeNewswire
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Estimating The Intrinsic Value Of Vaxart, Inc. (NASDAQ:VXRT) [Yahoo! Finance]Yahoo! Finance
- Vaxart, Inc. (NASDAQ:VXRT) Q4 2023 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
VXRT
Earnings
- 11/2/23 - Beat
VXRT
Sec Filings
- 4/18/24 - Form PRE
- 4/1/24 - Form 4/A
- 4/1/24 - Form 4
- VXRT's page on the SEC website